Taken together, tSNE analysis corroborated the finding that Vactosertib increases anti-tumor immunity against OS in TME through the accumulation of CD4+ T cells, CD8+ T cells and NK cell while suppressing the number of Tregs, MDSCs and M2-like TAMs in the OS TME. Here, CD4 is linked to neoplasm.